Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 6,517 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Not yet recruiting Phase 2 Interventional

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

NCT06710431
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Not applicable Interventional

A Study of Isoprinosine in Patients With Severe AIDS

NCT00002295
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus

NCT00814294
View directory record Official record
Conditions
Diabetes
Interventions
placebo, Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15), Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Muscle Shoals, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 23, 2026, 9:01 PM EDT
Terminated Phase 3 Interventional Results available

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

NCT02015637
View directory record Official record
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Not applicable Interventional

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Continuation Study of the Oral AKT Inhibitor GSK2110183

NCT01531894
View directory record Official record
Conditions
Cancer
Interventions
GSK2110183 (afuresertib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 23, 2026, 9:01 PM EDT
Withdrawn Phase 3 Interventional

Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia

NCT05707702
View directory record Official record
Conditions
Low-grade Oral Dysplasia
Interventions
Probiotic oral lozenges, Standard of care for oral dysplasia
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

NCT02131545
View directory record Official record
Conditions
Dementia, Delirium
Interventions
Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

NCT00073177
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
37
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

NCT04218851
View directory record Official record
Conditions
Invasive Aspergillosis
Interventions
Posaconazole IV, Posaconazole PFS, Posaconazole tablet
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Orange, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

NCT00856037
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Topotecan Hydrochloride
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2Phase 3 Interventional Results available

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

NCT00223977
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Sodium Ferric Gluconate Complex, Oral Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 2 Interventional

Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

NCT00205322
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 23, 2026, 9:01 PM EDT
Terminated Phase 1 Interventional

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT04570631
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Eftozanermin alfa, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 9:01 PM EDT
Active, not recruiting Phase 2 Interventional

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 9:01 PM EDT
Withdrawn Not applicable Interventional

Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy

NCT04272294
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Optical Spectroscopy
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 23, 2026, 9:01 PM EDT
Not listed Phase 1 Interventional

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

NCT01107522
View directory record Official record
Conditions
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Interventions
CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
Drug
Lead sponsor
Tactical Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
4
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

NCT01445405
View directory record Official record
Conditions
Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
Interventions
Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin, Radiation Therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

NCT00398502
View directory record Official record
Conditions
Metahdone-maintenance Subjects
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 23, 2026, 9:01 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

NCT05893537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Active Comparator CT1812, Placebo Comparator
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 9:01 PM EDT